Short answer
NeuroPace Inc (NPCE) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers NeuroPace’s financial results for the quarter ended September 30, 2026.
NeuroPace Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers NeuroPace’s financial results for the quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for revenue, profitability, cash flow and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $23.1M, down 1.1% YoY, with RNS revenue $22.9M, up 1.4%, signaling stalled commercial momentum
- GAAP net loss narrowed to $3.3M from $4.9M, while Adjusted EBITDA improved to $0.4M from negative $1.3M
- 2026 revenue guidance cut to $91M-$92M from $99.5M-$101.5M, reflecting account issues and field-organization disruption
- Cash, investments and restricted cash $49.5M versus $51.9M prior quarter, against $59.2M long-term borrowings
- Remote Care FDA submission and planned IGE amendment create regulatory growth catalysts, alongside AURORA adolescent-study enrollment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NeuroPace Inc 8-K filings
Get the next NPCE 8-K as it lands
Follow NPCE for push alerts, or ask the research agent what this filing means.